Patents by Inventor David J. Witter

David J. Witter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds specific to adenosine A1 receptors and uses thereof
    Publication number: 20040082599
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.
    Type: Application
    Filed: November 20, 2003
    Publication date: April 29, 2004
    Applicant: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Compounds specific to adenosine A3 receptor and uses thereof
    Patent number: 6686366
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A3 receptor and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: February 3, 2004
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Compounds specific to adenosine A1 receptors and uses thereof
    Patent number: 6680324
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: January 20, 2004
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Compounds specific to adenosine A1 receptors and uses thereof
    Patent number: 6680322
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: January 20, 2004
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Compounds specific to adenosine A3 receptor and uses thereof
    Patent number: 6673802
    Abstract: The subject invention provides a compound having the structure: or a pharmaceutically acceptable salt thereof and a method for treating a disease associated with the A3 adenosine receptor by administering a therapeutically effective amount of the compound.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: January 6, 2004
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
    Patent number: 6664252
    Abstract: This invention pertains to compounds having the structure: wherein NR1R2 is a substituted or unsubstituted 4-8 membered ring; wherein R3 is a substituted or unsubstituted four to six membered ring; wherein R5 is H, alkyl, substituted alkyl, aryl, arylalkyl, amino, substituted aryl; wherein R6 is H, alkyl, substituted alkyl, or cycloalkyl; with the proviso that NR1R2 is not 3-acetamido piperadino, 3-hydroxy pyrrolidino, 3-methyloxy carbonylmethyl pyrolidino, or 3-aminocarbonylmethyl pyrrolidino; with the proviso that NR1R2 is 3-hydroxymethyl piperadino only when R3 is 4-pyridyl; which specifically inhibit the adenosine A2a receptor and the use of these compounds to treat a disease associated with A2a adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: December 16, 2003
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Conformationallly constrained peptidomimetics as &bgr;-turn templates and modulators of SH3 domains
    Patent number: 6638941
    Abstract: Spirolactam compounds useful as inhibitors of protein-protein interactions modulated by SH3 domains are disclosed. Compounds of the invention are also useful as &bgr;-turn mimetics. Also disclosed are libraries of compounds of the invention, pharmaceutical compositions of the compounds of the invention, and methods for using the compounds of the invention to inhibit growth of a cell or to inhibit protein-protein interactions modulated by SH3 domains.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: October 28, 2003
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, David J. Witter
  • Compounds specific to adenosine A3 receptor and uses thereof
    Publication number: 20030073708
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A3 receptor and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.
    Type: Application
    Filed: November 30, 2001
    Publication date: April 17, 2003
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Compounds specific to adenosine A1 receptors and uses thereof
    Publication number: 20030045536
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.
    Type: Application
    Filed: November 30, 2001
    Publication date: March 6, 2003
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Compounds specific to adenosine A2a receptor and uses thereof
    Publication number: 20030036545
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A2a receptor and the use of these compounds to treat a disease associated with A2a adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.
    Type: Application
    Filed: December 4, 2000
    Publication date: February 20, 2003
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Compounds specific to adenosine A3 receptor and uses thereof
    Publication number: 20020094974
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A3 receptor and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.
    Type: Application
    Filed: December 1, 2000
    Publication date: July 18, 2002
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Compounds specific to adenosine A1 receptors and uses thereof
    Publication number: 20020058667
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.
    Type: Application
    Filed: December 1, 2000
    Publication date: May 16, 2002
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Pyrrolo [2, 3d] pyrimidine compositions and their use
    Publication number: 20020028782
    Abstract: Novel deazapurines are disclosed which are useful for the treatment of adenosine receptor stimulated diseases.
    Type: Application
    Filed: December 1, 2000
    Publication date: March 7, 2002
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter